The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

piquetherapeutics.com

Stage

Series B | Alive

Total Raised

$1.39M

Last Raised

$850K | 5 yrs ago

About Pique Therapeutics

Pique Therapeutics is a biotechnology company focused initially on the treatment of cancer. Pique's lead product is a therapeutic vaccine for non-small cell lung cancer in Phase 2 clinical trials. Pique is also utilizing its therapeutic vaccine technology in additional areas of oncology, with products in pre-clinical stage for pancreatic, colorectal, and head and neck cancers.

Pique Therapeutics Headquarter Location

201 W. Main Street Suite 300 PMB 317

Durham, North Carolina, 27701,

United States

919-386-9691

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pique Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pique Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Pique Therapeutics News

Sylvester Researcher’s Lung Cancer Immunotherapy Delivers Positive Results

Nov 7, 2017

Sylvester Researcher’s Lung Cancer Immunotherapy Delivers Positive Results 9:43 November 7, 2017 Pique Therapeutics, Inc. today announced encouraging results in a clinical trial of PT 107, an immunotherapy developed by a renowned scientist at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine to treat non-small cell lung cancer (NSCLC), the most common form of the disease. “We are very encouraged to see such positive results with a single agent in late stage non-small cell lung cancer,” said Christopher S. Meldrum, President of Pique Therapeutics. “The improvement in overall survival, particularly the significant 10-month benefit seen in non-squamous patients, highlight the promise of PT 107.” Pique Therapeutics  has licensed the research work of the late Eckhard R. Podack, M.D., Ph.D., one of the pioneering researchers in the field of immunotherapy. Podack was the discoverer of perforin-1 and perforin-2, two antibacterial proteins that help the body’s immune system defend against infectious diseases. He also created the technology underlying brentuximab (Adcetris®), used in the treatment of Hodgkin lymphoma. During his distinguished career as a researcher at Sylvester from 1987 until his death in 2015, Podack made a series of scientific discoveries pointing the way toward more effective treatments for lung cancer, infectious diseases and disorders of the immune system. He also served as professor and chair of the Miller School’s Department of Microbiology and Immunology. “Dr. Podack was one of the Miller School’s most prolific researchers and entrepreneurs,” said Norma Kenyon, Ph.D., chief innovation officer at the Miller School of Medicine, and vice provost for innovation at the University of Miami. “One of our university’s top priorities is conducting groundbreaking research, and moving those discoveries forward so they can help patients.” While serving as director of the Miller School’s Wallace Coulter Center for Translational Research, Kenyon helped Podack take cells from the laboratory and move them to a CGMP [current good manufacturing practice] facility to advance their development for clinical use. “Chris Meldrum understands that biomedical technologies can take eight to ten years to move from the laboratory bench to the patient’s bedside,” Kenyon said. “He has the tenacity and vision to keep moving forward with immunotherapies that can have a huge impact on patients’ lives.” Pique’s lead product, PT 107, is a first-in-class therapeutic cellular vaccine for the treatment of NSCLC, which constitute about 85 percent of all lung cancers. In previous trials, PT 107 was well tolerated by participants, and exhibited a very good safety profile in cancer patients. Pique’s new multicenter Phase 2 study showed meaningful improvement in length of survival for patients with stage IIIB/IV non-small cell lung cancer whose disease had progressed following previous therapy. Patients receiving treatment with PT 107 had a median overall survival of 12.5 months versus 8.4 months for patients who received a placebo. There was also a significant improvement in the time to progression of the disease. Safety results were consistent with previous clinical experience, with no drug-related serious adverse events being reported. “We will now seek to move PT 107 forward in collaboration with a partner,” said Meldrum. “The results of this trial indicate that this first-in-class therapeutic vaccine has tremendous potential as a therapy for non-small cell lung cancer, both as a stand-alone treatment, as well as in conjunction with other treatments, such as standard of care checkpoint inhibitors.”

  • Where is Pique Therapeutics's headquarters?

    Pique Therapeutics's headquarters is located at 201 W. Main Street , Durham.

  • What is Pique Therapeutics's latest funding round?

    Pique Therapeutics's latest funding round is Series B.

  • How much did Pique Therapeutics raise?

    Pique Therapeutics raised a total of $1.39M.

  • Who are the investors of Pique Therapeutics?

    Investors of Pique Therapeutics include Wilmington Investor Network, Piedmont Angel Network and Golden Pine Ventures.

  • Who are Pique Therapeutics's competitors?

    Competitors of Pique Therapeutics include MaxCyte, Seattle Genetics, Cell Point, Stemline Therapeutics, ARIAD Pharmaceuticals, OxThera, Mirna Therapeutics, Immutep, Incline Therapeutics, Arcion Therapeutics and 21 more.

You May Also Like

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

C
Chroma Therapeutics

Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.

C
Cell Point

Cell Point is a biotechnology company, develops radiodiagnostic imaging and intracellular therapeutic agents, and delivery systems for the administration of local regional radio/chemotherapy.

S
Spaltudaq

Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.

A
Arisyn Therapeutics

Arisyn Therapeutics Inc. is a biotechnology company focused on the development of first in class inhibitors of infectious disease and cancer. Arisyn possesses a portfolio of small molecule compounds that will be developed to treat Human Immunodeficiency Virus-Type 1 (HIV-1), Human Immunodeficiency Virus-Type 2 (HIV-2), Human T-Lymphotropic Virus-Type 1 (HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Herpes Simplex Virus-Type 2 (HSV-2). Arisyn will perform all necessary studies required to develop these therapeutic agents through Phase 1 and Phase 2 human clinical trials.

I
InCode BioPharmaceutics

Incode BioPharmaceutics, Inc., has developed a product candidate, HC3-1496, that specifically targets the complement pathway. The mechanism-of-action of HC3-1496 results in enzymatic depletion of the complement protein C3, the key component for all three pathways of complement activation (alternative, classical, and mannose-lectin). The company's preclinical results show rapid depletion of C3 without any observed adverse events, including in primates. Importantly, HC3-1496 depletes C3 without the downstream activation of C5, thus preventing the formation of the C5a anaphylatoxin. A recent exciting result is the demonstration that HC3-1496 enhances the efficacy of an anti-CD20 mAb in a murine cancer model. These data will be presented at the upcoming American Society of Hematology (ASH) meeting in December. This clinical avenue is a high priority for InCode, and also underscores the increased appreciation for the role of complement in certain oncologic settings. The company have also demonstrated efficacy in several other animal models of human disease, including collagen-induced arthritis (RA), myocardial ischemia/reperfusion, and age related macular degeneration (AMD). The company have also demonstrated that HC3-1496 prevents the lysis of erythrocytes in patients with paroxysmal nocturnal hemoglobinuria (PNH). Given the emerging role of complement activation in the pathogenesis of grievous human disease, Incode intends to exploit the potent activity of HC3-1496. The company intend to initiate human clinical trials in selected indications within 18 months.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.